Revolution Medicines (RVMD) Research & Development (2019 - 2026)

Revolution Medicines' Research & Development history runs 8 years deep, the most recent figure standing at $344.0 million for Q1 2026.

• On a quarterly basis, Research & Development rose 67.18% year-over-year to $344.0 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 65.39% increase from a year earlier, with the FY2025 full-year figure at $987.3 million, up 66.72% from the prior year.
• Research & Development grew to $344.0 million in Q1 2026 per RVMD's latest filing, from $294.9 million in the prior quarter.
• Across five years, Research & Development topped out at $344.0 million in Q1 2026 and bottomed at $56.5 million in Q1 2022.
• The 5-year median for Research & Development is $134.9 million (2024), against an average of $153.0 million.
• Biggest YoY gain for Research & Development was 124.54% in 2023; the steepest drop was 22.05% in 2023.
• Year by year, Research & Development stood at $66.1 million in 2022, then jumped by 124.54% to $148.5 million in 2023, then advanced by 26.68% to $188.1 million in 2024, then soared by 56.8% to $294.9 million in 2025, then grew by 16.62% to $344.0 million in 2026.
• Per Business Quant, the three latest RVMD Research & Development figures stand at $344.0 million (Q1 2026), $294.9 million (Q4 2025), and $262.5 million (Q3 2025).